Detalles de la búsqueda
1.
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.
CA Cancer J Clin;
72(5): 454-489, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35708940
2.
One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract.
Curr Treat Options Oncol;
25(2): 206-219, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38315403
3.
Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma.
Oncologist;
27(5): e406-e409, 2022 05 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35294031
4.
Failure of Androgen-Deprivation Therapy Due to Ectopic hCG Secretion.
N Engl J Med;
388(7): 660-662, 2023 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36791169
5.
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
BJU Int;
128(5): 607-614, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33909949
6.
Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Oncologist;
25(5): 422-430, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31971318
7.
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma.
Invest New Drugs;
38(6): 1807-1814, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32472319
8.
Highlights in metastatic urothelial cancer from the European Society for Medical Oncology Congress 2023: commentary.
Clin Adv Hematol Oncol;
21 Suppl 6(12): 15-17, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38307621
9.
JAVELIN: avelumab another spear to fight urothelial carcinoma.
Lancet Oncol;
19(1): 5-7, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29217289
10.
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Cancer Treat Rev;
122: 102652, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37980876
11.
Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer.
J Immunother Cancer;
12(2)2024 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38309723
12.
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Cancer Cell;
42(5): 732-735, 2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38579722
13.
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.
Cancer Immunol Res;
: OF1-OF15, 2024 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38552171
14.
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Clin Genitourin Cancer;
21(1): 106.e1-106.e8, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35945133
15.
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.
Cancer Immunol Res;
11(8): 1114-1124, 2023 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37279009
16.
Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial.
JCO Oncol Pract;
19(11): 1069-1079, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37733980
17.
The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma.
Cancers (Basel);
14(24)2022 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36551504
18.
Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors.
Clin Genitourin Cancer;
20(4): 301-306, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35614012
19.
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial.
Clin Cancer Res;
28(4): 738-747, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34789480
20.
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
JCO Precis Oncol;
6: e2100448, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35171658